Levonorgestrel

Intrauterine devices and tubal ligation were similarly effective in preventing pregnancy, although the rate of complications was lower with intrauterine contraception, findings of a retrospective cohort study showed.

A post-hoc analysis of the Twirla contraceptive patch showed that it was well tolerated among women with a BMI of 25 to 30 kg/m2 as well as those with a BMI less than 25 kg/m2, according to researchers.

Treatment with a levonorgestrel-dispensing intrauterine device appeared to be effective and safe for women with stage I endometrial adenocarcinoma or endometrial hyperplasia with atypia, according to results of a randomized, phase 2 study.

Levonorgestrel intrauterine devices were noninferior to copper IUDs as emergency contraception, according to research published in the New England Journal of Medicine.

The FDA approved a supplemental new drug application for the hormone-releasing intrauterine device Liletta 52 mg that extends the device’s duration for pregnancy prevention for a maximum of 6 years, according to a press release.

WHO revised its recommendations on hormonal contraceptive use to say that women at high risk for HIV can use any form of reversible contraception — including implants, intrauterine devices and progestogen-only injectables — without an increased risk for infection.